Immune ablation and hematopoietic stem cell transplant ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00278551 (ClinicalTrials.gov) | June 1997 | 15/1/2006 | Stem Cell Support in Patients With Rheumatoid Arthritis | Immune Ablation and Hematopoietic Stem Cell Support in Patients With Rheumatoid Arthritis and High Risk Factors | RHEUMATOID ARTHRITIS | Biological: Immune ablation and hematopoietic stem cell transplant | Richard Burt, MD | NULL | Terminated | 18 Years | 60 Years | Both | 10 | Phase 1 | United States |